New Vaccine

1st Hib Vaccine Developed with Indigenous Technology

Bharat Biotech International Limited (BBIL) recently announced the launch of BioHib, the first indigenously developed and manufactured Haemophilus Influenza type b (Hib) vaccine in India.

BioHib is a conjugate vaccine that has proven its safety and efficacy in multi-centric clinical trials. BioHib is a safe and efficacious vaccine developed with conjugation and manufacturing technologies developed at Bharat Biotech. BioHib will be a safe and affordable vaccine that offers complete protection against Hib infections. Hib bacterium causes serious diseases, often life-threatening illnesses in young children. It can cause meningitis and severe pneumonia, leading to three million cases of serious illness and 4,00,000 deaths each year in children under five years of age. Hib is difficult to treat in the developing world, with infected children in developing countries are several times worse than those in industrialised countries. While other Indian manufacturers have imported conjugation and manufacturing technologies from Europe, and USA, the scientific, manufacturing and product development teams at Bharat Biotech have developed all processes required to manufacture BioHib in-house at Bharat Biotech.

Bharat Biotech also announced the launch of its tetravalent combination vaccine, Comvac4-HB containing Diphtheria, Pertussis, Tetanus and Hepatitis B in one vaccine. These two new vaccines, BioHib and Comvac4-HB, enable the deployment of a combination pentavalent vaccine in a single injection. "The launch of BioHib is a significant milestone for Bharat Biotech and more importantly for India, since all technologies were developed within India. BioHib has the ability to save the lives of millions of children at a very affordable price," said Dr Krishna M Ella, Chairman and Managing Director of Bharat Biotech.

EH News Bureau